Astellas Pharma (OTCMKTS:ALPMY) Releases Earnings Results

Astellas Pharma (OTCMKTS:ALPMY) released its quarterly earnings data on Tuesday. The company reported $0.30 EPS for the quarter, Zacks reports. Astellas Pharma had a return on equity of 10.40% and a net margin of 3.26%.

Astellas Pharma Stock Performance

ALPMY stock opened at $9.52 on Tuesday. Astellas Pharma has a 1 year low of $9.05 and a 1 year high of $13.14. The company has a market cap of $17.22 billion, a P/E ratio of 45.31 and a beta of 0.34. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.10 and a quick ratio of 0.86. The stock’s fifty day moving average price is $9.87 and its 200-day moving average price is $10.97.

About Astellas Pharma

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.